The field of targeted cancer therapy is continuously advancing, with cyclin-dependent kinase (CDK) inhibitors leading the charge in offering more precise and effective treatments. Among these, inhibitors targeting CDK4 and CDK6 have shown significant promise, particularly in breast cancer. The structural backbone of many of these potent inhibitors is derived from compounds like Pyrido[2,3-d]pyrimidin-7(8H)-one. Specifically, the derivative identified by CAS 571190-30-2, chemically named 6-acetyl-8-cyclopentyl-5-methyl-2-[[5-(1-piperazinyl)-2-pyridinyl]amino]-Pyrido[2,3-d]pyrimidin-7(8H)-one, is a critical pharmaceutical intermediate in this arena.

NINGBO INNO PHARMCHEM CO.,LTD. is at the forefront of supplying these vital intermediates, ensuring that researchers and manufacturers have access to high-quality materials. Our offering of this Pyrido[2,3-d]pyrimidin-7(8H)-one derivative, presented as a white powder with a purity of ≥99%, is crucial for the successful synthesis of molecules like Palbociclib. The development of these inhibitors involves complex chemical pathways, and the purity and consistency of intermediates are paramount to achieving the desired therapeutic outcomes.

The applications for Pyrido[2,3-d]pyrimidin-7(8H)-one derivatives are not limited to established drugs; they also fuel ongoing research into novel CDK inhibitors. Scientists are constantly exploring modifications to these core structures to enhance selectivity, reduce side effects, and broaden their therapeutic applicability. When researchers seek information, they often use terms such as 'Pyrido[2,3-d]pyrimidin-7(8H)-one derivatives applications' or 'CDK inhibitor intermediates'. Our role as a reliable manufacturer and supplier is to meet this demand by providing the foundational chemistry needed for these explorations.

The importance of these intermediates is amplified by their use as reference standards. In pharmaceutical quality control, having access to highly pure reference materials is essential for verifying the identity, purity, and potency of APIs. Our commitment at NINGBO INNO PHARMCHEM CO.,LTD. extends to ensuring that our products meet these rigorous analytical requirements. As the landscape of CDK inhibitors continues to expand, with new agents entering clinical trials and gaining regulatory approval, the demand for precursors like CAS 571190-30-2 is expected to grow significantly. We are prepared to support this growth by maintaining a robust supply chain and upholding the highest manufacturing standards.

In essence, the Pyrido[2,3-d]pyrimidin-7(8H)-one derivative is more than just a chemical compound; it is an enabler of innovation in targeted cancer therapy. NINGBO INNO PHARMCHEM CO.,LTD. is proud to contribute to this vital field by providing the high-quality intermediates necessary for the development of life-saving medicines.